Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthSpring Sutimlimab Coverage Update | OpenPaye…
    Ask Trek AI about this page
    ModifiedHealthSpringPolicy RX501.180

    Sutimlimab-jome

    Customize your policy alerts

    Sign up for healthspring Policy RX501.180 alerts

    Get alerted when Policy RX501.180 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity coverage and authorization of sutimlimab-jome (Enjaymo) for adults with confirmed cold agglutinin disease and hemolysis. Non-approved FDA indications are considered experimental, investigational, and/or unproven.

    Policy Summary
    PayerHealthSpring
    PolicySutimlimab-jome
    Policy CodePolicy RX501.180
    Change TypeModified
    Effective DateSep 15, 2026
    Next Review DateNot specified
    Key ActionSubmit documentation confirming adult status, chronic hemolysis, a C3d-specific monospecific direct antiglobulin test, and a cold agglutinin titer of at least 64 at 4°C.
    SourceLink
    POLICY UPDATE CHANGES

    The coverage criteria no longer require a positive polyspecific direct antiglobulin test (DAT).

    3Required diagnostic findings
    ≥64Cold agglutinin titer
    J1302HCPCS code
    All otherNon-approved FDA indications

    Coverage Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Initial therapy for cold agglutinin disease

    Sutimlimab-jome may be considered medically necessary when all of the following are met.

    Covered adult indication

    • Confirmed cold agglutinin disease

      • Chronic hemolysis is documented.
      • A monospecific direct antiglobulin test is specific for C3d.
      • The cold agglutinin titer is at least 64 at 4°C.≥64 at 4°C
    • Exclude secondary causes: Cold agglutinin syndrome is not secondary to infection, rheumatologic disease, systemic lupus erythematosus, another autoimmune disorder with antinuclear antibodies, or overt hematologic malignancy.

    Medically necessary treatment of hemolysis

    May be considered medically necessary when the individual meets the clinical criteria.

    Medically necessary use: The patient is an adult receiving sutimlimab-jome for treatment of hemolysis and meets the clinical criteria in the policy.

    The specific clinical criteria are not provided in this document window.

    Medically Necessary Use

    Sutimlimab-jome may be considered medically necessary when the individual meets the clinical criteria.

    Treatment of hemolysis in adults: The individual is an adult receiving sutimlimab-jome for treatment of hemolysis.

    The document does not provide the remaining clinical criteria in this window.

    Coverage does not apply when cold agglutinin syndrome is secondary to infection, rheumatologic disease, systemic lupus erythematosus (SLE), another autoimmune disorder with antinuclear antibodies, or overt hematologic malignancy.

    All other non-approved U.S. Food and Drug Administration (FDA) indications for sutimlimab-jome (Enjaymo) are considered experimental, investigational, and/or unproven.

    Sutimlimab-jome may be considered medically necessary for treatment of hemolysis in adults when the applicable clinical criteria are met. Use for any other non-approved FDA indication is considered experimental, investigational, and/or unproven.

    Requests for sutimlimab-jome for non-approved FDA indications are considered experimental, investigational, and/or unproven.

    Coding and Clinical Thresholds

    CPT CodesCPT
    No codes listed
    HCPCS CodesHCPCS
    J1302Description not stated in this document window.
    Cold agglutinin titer
    Required titerAt least 64
    Testing temperature4°C
    Coverage applicationRequired to confirm cold agglutinin disease in adults with hemolysis
    Hemoglobin response threshold
    Hemoglobin level criterionHemoglobin level ≥12 g/dL
    Hemoglobin increase criterionIncrease from baseline in hemoglobin level ≥2 g/dL
    Assessment timingTreatment assessment time point based on the mean value from Weeks 23, 25, and 26
    Transfusion avoidance period
    Transfusion requirementNo red blood cell transfusion
    Avoidance periodFrom Week 5 through Week 26
    CARDINAL result17 of 24 patients (71%) avoided red blood cell transfusion during this period

    Provider Documentation and Authorization Actions

    Prior Authorization

    Confirm Cold Agglutinin Disease

    Submit prior authorization documentation confirming that the patient is an adult with cold agglutinin disease (CAD) and is being treated for hemolysis.

    • Document chronic hemolysis.
    • Include a monospecific direct antiglobulin test (DAT) specific for C3d.
    • Include a cold agglutinin titer ≥64 at 4°C.
    Documentation Required

    Diagnostic and Exclusion Documentation

    Provide diagnostic findings establishing CAD and documentation that the cold agglutinin syndrome is not secondary to an excluded condition.

    • Confirm chronic hemolysis, C3d-specific monospecific DAT, and cold agglutinin titer ≥64 at 4°C.
    • Document exclusion of infection, rheumatologic disease, systemic lupus erythematosus (SLE), other autoimmune disorders with anti-nuclear antibodies, and overt hematologic malignancy.
    Documentation Required

    Clinical Eligibility Documentation

    Submit clinical documentation showing that the adult patient is being treated for hemolysis and meets the applicable medical-necessity criteria for sutimlimab-jome (Enjaymo®).

    • Document adult status and treatment of hemolysis.
    • Include the required clinical findings supporting confirmed CAD.
    Billing Rule

    Benefit Document Review

    Review the member’s benefit contract or Summary Plan Description (SPD) when making a coverage determination based on the policy.

    • Verify defined coverage and non-coverage provisions.
    • Check benefit exclusions and limitations, including dollar or duration caps.
    Denial Risk

    Unconfirmed or Secondary Cold Agglutinin Disease

    Requests are at risk of denial when CAD is unconfirmed, required diagnostic findings are absent, or the cold agglutinin syndrome is secondary to an excluded condition.

    • Confirm chronic hemolysis, C3d-specific monospecific DAT, and cold agglutinin titer ≥64 at 4°C.
    • Exclude infection, rheumatologic disease, SLE, other autoimmune disorders with anti-nuclear antibodies, and overt hematologic malignancy.
    Denial Risk

    Non-Approved FDA Indication

    Sutimlimab-jome (Enjaymo®) is considered experimental, investigational, and/or unproven for all other non-approved U.S. Food and Drug Administration (FDA) indications.

    • Coverage may be denied for indications outside the approved FDA indications.
    Denial Risk

    Non-Approved Indication

    Coverage may be denied when sutimlimab-jome is requested for a non-approved FDA indication rather than for the policy-supported treatment of hemolysis in adults who meet the clinical criteria.

    • Verify that the requested use aligns with the approved indication and applicable clinical criteria.
    Denial Risk

    Non-Approved Indication Coverage Risk

    Requests for non-approved indications may be denied as experimental, investigational, and/or unproven.

    • Review the member benefit contract or Summary Plan Description and applicable coverage provisions before finalizing the determination.
    • Medicare coverage may be subject to local carrier discretion where no national Medicare coverage position applies.

    Clinical Background

    Cold agglutinin disease is characterized by chronic hemolysis and laboratory evidence of red-cell antibody activity involving C3d. Confirmation requires a monospecific direct antiglobulin test specific for C3d and a cold agglutinin titer of at least 64 at 4°C.

    Definitions

    Confirmed cold agglutinin disease
    Chronic hemolysisRequired diagnostic finding
    Direct antiglobulin testMonospecific DAT specific for C3d
    Cold agglutinin titerAt least 64 at 4°C
    Cold agglutinin disease (CAD)
    Disease typeRare autoimmune disorder and subtype of autoimmune hemolytic anemia
    Antibody activityCold-reactive antibodies bind to red blood cells
    Clinical effectThe antibody-tagged red blood cells are destroyed
    Hemolysis
    DefinitionPremature destruction of red blood cells
    CAD mechanismAntibody-tagged red blood cells are activated through complement
    Cell destructionComplement-activated red blood cells are destroyed by immune cells
    Sutimlimab-jome
    Drug classImmunoglobulin G subclass 4 (IgG4) monoclonal antibody
    MechanismInhibits the classical complement pathway
    TargetBinds complement protein C1s, a serine protease that cleaves C4
    Responder
    Hemoglobin responseIncrease from baseline in hemoglobin ≥2 g/dL or hemoglobin level ≥12 g/dL at the treatment assessment time point
    Transfusion requirementNo blood transfusion from Week 5 through Week 26
    Additional treatment requirementNo treatment for cold agglutinin disease beyond what was permitted by protocol from Week 5 through Week 26
    Protocol-prohibited CAD medications
    Rituximab monotherapyProhibited by the protocol
    Rituximab combination therapyRituximab combined with cytotoxic agents was prohibited
    Protocol periodPatients were assessed for use of prohibited CAD medications from Week 5 through Week 26

    Initial Therapy Criteria

    Initial therapy — treatment of hemolysis

    Sutimlimab-jome may be considered medically necessary for treatment of hemolysis when all criteria below are met.

    Initial sutimlimab-jome coverage

    • Diagnostic confirmation

      • Chronic hemolysis: The individual has chronic hemolysis.
      • C3d-specific DAT: The monospecific direct antiglobulin test is specific for C3d.
      • Titer requirement: The cold agglutinin titer is at least 64 at 4°C.≥64 at 4°C
    • No listed secondary cause: The cold agglutinin syndrome is not secondary to infection, rheumatologic disease, systemic lupus erythematosus, another autoimmune disorder with antinuclear antibodies, or overt hematologic malignancy.

    Initial medically necessary therapy

    Sutimlimab-jome may be considered medically necessary for treatment of hemolysis in adults when clinical criteria are met.

    Initial therapy eligibility: Adult patient; treatment is for hemolysis; applicable clinical criteria are met.

    Specific criteria are not included in this document window.

    Initial Therapy

    Sutimlimab-jome may be considered medically necessary for treatment of hemolysis in adults when the individual meets the clinical criteria.

    Adult treatment of hemolysis: The individual is an adult and sutimlimab-jome is being used to treat hemolysis.

    The detailed clinical criteria are not present in this window.

    Policy Summary
    PayerHealthSpring
    PolicySutimlimab-jome
    Policy CodePolicy RX501.180
    Change TypeModified
    Effective DateSep 15, 2026
    Next Review DateNot specified
    Key ActionSubmit documentation confirming adult status, chronic hemolysis, a C3d-specific monospecific direct antiglobulin test, and a cold agglutinin titer of at least 64 at 4°C.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Documentation and Authorization ActionsClinical BackgroundDefinitionsInitial Therapy Criteria